As excessive, IRG1 overproduction-mediated itaconate production is linked to many diseases, including gout, chronic arthritis, and cancer, in mouse models, IRG1 has been suggested as an optimal target for therapeutic intervention [17–19]. Here, ACOD1 is linked to cancer.